Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European ...

A retrospective analysis showed improved overall survival (OS) with Orca-T compared with post-transplant cyclophosphamide in ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, "Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track ...

Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...

In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

Dr. Thomas Hartung explains how AI and microphysiological systems (MPS) are changing drug safety testing. These ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...